Onco Actu du 13 mai 2019

	3. PRÉVENTION
Smoke, Drink and Eat What You Want, Norway’s Public Health Minister Says [NY Times] “I fear that this will set public health efforts back for decades, and that this will compromise the general understanding among Norwegians of the health consequences of tobacco and alcohol use,” Anne Lise Ryel, secretary general of Norway’s Cancer Society, said in a statement.
	3.1.1 PRÉVENTION - TABAC - E-CIGS
Juul’s ‘switch’ campaign for smokers draws new scrutiny [AP] Under intense scrutiny amid a wave of underage vaping, Juul is pushing into television with a multimillion-dollar campaign rebranding itself as a stop-smoking aid for adults trying to kick cigarettes.
	4.15 DÉP., DIAG. & PRONO. - IMAGERIE
New Brain Tumor Imaging Technique Uses Protein Found in Scorpion Venom [Cedars-Sinai] The new imaging technique that was studied uses a special high-sensitivity near-infrared camera developed at Cedars-Sinai, along with the imaging agent tozuleristide, or BLZ-100, developed by Blaze. The agent contains a synthetic version of an amino acid compound found in scorpion venom.
	4.2 DÉP., DIAG. & PRONO. - GÉNOME
How genomics profiling can help identify the best treatment for bladder cancer [Baylor College of Medicine] The researchers also applied their single-patient classifier to the data produced by the IMvigor 210 clinical trials that treated nearly 400 patients with locally advanced or metastatic bladder cancer with atezolizumab, a type of immunotherapy drug, and reported objective response and overall survival. This enabled the researchers to connect response to treatment with a particular bladder cancer subtype.
	4.5 DÉP., DIAG. & PRONO. - COLORECTAL
Guardant Health Announces Plans for Prospective Colorectal Cancer Screening Study [Genome Web] The firm is planning for a cohort of more than 10,000 patients and expects to start the trial in the second half of 2019.
	4.9 DÉP., DIAG. & PRONO. - SEIN
New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy [Myriad] New Study Finds Approximately 62 Percent of Women May Not Need Extended Endocrine Therapy Five Years After Diagnosis.
	5.10 TRAITEMENTS - ESSAIS
Jeffrey Aronson: When I use a word . . . Reported outcomes [BMJ] At the end of these explorations I came to the conclusion that it would be helpful to introduce two new concepts to clarify the ideas that the various terms imply: minimum desirable benefits and maximum acceptable harms.
Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival [JAMA Network Open] More than 40% of the negative phase 3 RCTs in oncology published in these 5 journals were conducted without a supporting phase 2 trial and were sponsored by both academia and industry. Running such trials not only may risk loss of resources owing to a failed trial but also may be associated with decreased patient survival.
	5.12 IMMUNOTHÉRAPIES
New Drugs, New Side Effects: Complications of Cancer Immunotherapy [NCI] To more effectively explore such questions, doctors and researchers need to establish definitions of immunotherapy-related side effects and develop standards for reporting these side effects as they are observed in patients, Dr. Sharon noted.
	5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS
Forty Seven Inc. and Acerta Enter Collaboration to Evaluate Novel Immuno-Oncology Triple Combination in Diffuse Large B-cell Lymphoma [Forty Seven] Plan to evaluate Forty Seven’s CD47 antibody in combination with rituximab and Calquence (acalabrutinib) .
	5.2 PHARMA
A newly formed biotech launched out of George Daley’s Harvard lab adds global players to its syndicate, bringing its haul to $83M [EndPoints] The work at 28-7 begins with a target discovered in the lab of Harvard’s George Daley. He found that if you inhibit the RNA modulating protein LIN28 you should be able to free the reins on the miRNA Let-7, which plays a role in attacking cancer cells.
Philogen who? A low profile but pharma-connected Italian-Swiss hybrid steps out with $68M for a final push over the PhIII finish line [EndPoints] Daromun, the lead drug, combines a pair of their immunocytokines — The IL2 fusion protein Darleukin and the TNF fusion protein Fibromun — for the intralesional treatment of Stage III B and C melanoma patients who are trying to fight off progression to Stage IV, where their prospects of survival are grim.
	5.2.3 PHARMA - ÉCONOMIE
Puma Biotech’s new cancer drug Nerlynx suffered a terrible quarter. What gives? [Fierce Pharma] Executives on the Q1 call offered a lot of explanations, including an increase in the number of patients discontinuing therapy. That was the driving force behind the slowdown, the execs said, promising the company is working hard to improve those stats. But analysts want to wait until Q2 numbers come in before giving management a pass.
Puma investors fret, as Nerlynx Q1 sales fall uncomfortably short of Wall Street estimates [EndPoints] The drug, which was in-licensed by Puma from Pfizer, was approved by the FDA in July 2017, to prevent breast cancer relapse, following therapy in patients with HER2-positive cancer.
	5.3 TRAITEMENTS - FDA, EMA, NICE...
Evaluating Reproductive Toxicity in Oncology Drugs: FDA Finalizes Guidance [RAPS] The guidance deals with evaluating embryo-fetal development (EFD) and assessing the need for an EFD study with a weight of evidence (WOE) approach, which is further explained in detail in the guidance.
	5.5.1.1 ASCO (GÉNÉRAL) - INDUSTRIELS
Roche to present new data highlighting comprehensive approach to cancer care at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting [Roche] - New pivotal data on fixed-duration combination of Venclexta/Venclyxto plus Gazyva/Gazyvaro in previously untreated chronic lymphocytic leukaemia. - New data for entrectinib in paediatric patients with recurrent or refractory solid tumours harbouring NTRK, ROS1 or ALK gene fusions
	6. LUTTE CONTRE LES CANCERS
Brain cancer 'pink drink' campaigned for by Tessa Jowell rolled out on NHS in memory of Labour peer [The Telegraph] Around 2,000 brain cancer patients a year stand to benefit from the “pink drink” solution, which the Labour peer described as the “gold standard” of treatment. The 5-ALA dye makes cancerous cells glow under UltraViolet light, enabling surgeons accurately to target diseased areas.
	6.1 OBSERVATION
Diabetes Linked to Numerous Cancers in Large Chinese Study [Wiley] In the largest study to date concerning the association between type 2 diabetes and cancer risk in mainland China, investigators examined information from the Shanghai Hospital Link database. They identified 410,191 adults with type 2 diabetes (and without a history of cancer) from July 2013 to December 2016. Patients were followed until December 2017 to assess for the development of cancer.
	6.5 MÉDECINES ALTERNATIVES/COMPLÉMENTAIRES
Noah McAdams: Another story of “parental rights” to choose quackery versus the rights of a child with cancer [Respectful Insolence] I fear very much that after Noah undergoes his next two cycles of chemotherapy, Judge Campbell will see a bone marrow aspirate with no leukemic cells and be tempted to let his parents treat him with cannabis and all the other cancer quackery they wanted to use instead of chemotherapy.
	6.6 PUBLICATIONS
Brazilian biomedical science faces reproducibility test [Nature] Researchers at more than 60 Brazilian labs will assess the replicability of research by their country’s scientists.
Understanding cancer research activities on a global scale just got a little easier [Dimensions] Dimensions has integrated the CSO classification from the International Cancer Research Partnership (ICRP).
Academics Raise Concerns About Predatory Journals on PubMed [The Scientist] The National Library of Medicine has quality control procedures in place, but some researchers believe additional scrutiny is necessary.